<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00605423</url>
  </required_header>
  <id_info>
    <org_study_id>NA 00012714</org_study_id>
    <nct_id>NCT00605423</nct_id>
  </id_info>
  <brief_title>The MAP Study: Fluocinolone Acetonide (FA)/Medidur (TM) for Age Related Macular Degeneration (AMD) Pilot</brief_title>
  <acronym>MAP</acronym>
  <official_title>A Single Masked, Randomized Comparison of the Safety and Efficacy of 0.2 and 0.5 µg/Day Fluocinolone Acetonide/Medidur™ in Patients With Exudative Age Related Macular Degeneration Who Have Received Lucentis™</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Alimera Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>pSiVida Limited</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Treatment of exudative age-related macular degeneration has been significantly improved by
      the advent of Lucentis™( which provides improved vision rather than simply stabilization) is
      common; however, monthly injections may be required to maintain this effect. It is
      hypothesized that sustained release fluocinolone acetonide will allow maintenance of the
      improved vision with fewer Lucentis injections.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Treatment of exudative age-related macular degeneration has been significantly improved by
      the advent of Lucentis™( which provides improved vision rather than simply stabilization) is
      common; however, monthly injections may be required to maintain this effect. The use of the
      glucocorticoids such as triamcinolone acetonide as adjunct treatment for exudative
      age-related macular degeneration has been reported to enhance the efficacy of photodynamic
      therapy with Visudyne® (verteporphin for injection). It is hypothesized that sustained
      release fluocinolone acetonide will allow maintenance of the improved vision with fewer
      Lucentis injections. This study is a pilot phase 2b study to test this hypothesis. The safety
      assessments will continue through 36 months.This study will compare the safety 2 doses of
      FA/Medidur in conjunction with Lucentis (as needed) in patients with neovascular AMD who have
      have been treated with Lucentis for at least 6 months and have reached a plateau.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change From Baseline in Visual Acuity</measure>
    <time_frame>6 mos</time_frame>
    <description>Visual acuity is measured using ETDRS charts at 4 meters.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Developing Cataracts</measure>
    <time_frame>6 mos</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in IOP From Baseline</measure>
    <time_frame>6 mos</time_frame>
    <description>IOP stands for intra ocular pressure</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Age Related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dose 0.2 ug/day Medidur implant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dose 0.5 ug/day Medidur implant</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluocinolone Acetonide/Medidur</intervention_name>
    <description>0.2 ug/day implant</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluocinolone Acetonide/Medidur</intervention_name>
    <description>0.5 ug/day implant</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients 50 or greater

          -  Treated with intraocular injections of Lucentis for at least 6 months and have reached
             a plateau, defined as 2 consecutive visits (4-6 weeks apart) with no improvement in VA
             (worse or within one line better) or center subfield thickening (worse or within 30 um
             better).

          -  Best Corrected Visual Acuity 20/320 or better in the study eye

        Exclusion Criteria:

          -  Pregnant, lactating females or females of child bearing potential (unless using
             reliable contraception, i.e. double barrier, surgical sterilization, oral
             contraceptives, Norplant , intrauterine device (IUD).

          -  Glaucoma or ocular hypertension (defined as IOP &gt; 21 mmHg or concurrent therapy at
             screening with IOP-lowering agents) in the study eye

          -  Laser or photodynamic therapy within 12 weeks of screening

          -  Any ocular surgery in the study eye within 12 weeks of screening

          -  Yag capsulotomy in the study eye within 15 days of screening

          -  Treatment with intravitreal, subtenon, or periocular steroid or anti-VEGF therapy
             other than Lucentis within 6 months prior to enrollment (e.g., triamcinolone
             injection, Avastin, Macugen.) Systemic treatment with Avastin is also not allowed
             within 6 months prior to screening or at any time during the study.

          -  Any change in systemic steroid therapy within 3 months of screening

          -  Retinal or choroidal neovascularization due to ocular conditions other than AMD.

          -  Any active viral, fungal or bacterial disease of the cornea or conjunctiva or any
             history of a potentially recurrent infection which could be activated by treatment
             with a steroid, (e.g., ocular herpes simplex virus).

          -  Known or suspected hypersensitivity to any of the ingredients of Lucentis, the
             investigational product or to other corticosteroids.

          -  History of vitrectomy in the study eye

          -  History of uncontrolled IOP elevation with steroid use that did not respond to topical
             therapy

          -  History or presence of any disease or condition (malignancy) that in the
             investigator's opinion would preclude study treatment or follow-up

          -  Any lens opacity which impairs visualization of the posterior pole

          -  Participation in another clinical trial within 12 weeks before the screening visit or
             during the study

          -  Subjects who are a poor medical risk because of other systemic diseases or active
             uncontrolled infections.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter A Campochiaro, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wilmer Eye Institute, Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 17, 2008</study_first_submitted>
  <study_first_submitted_qc>January 30, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 31, 2008</study_first_posted>
  <results_first_submitted>September 20, 2013</results_first_submitted>
  <results_first_submitted_qc>March 10, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 7, 2014</results_first_posted>
  <last_update_submitted>March 10, 2014</last_update_submitted>
  <last_update_submitted_qc>March 10, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 7, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johns Hopkins University</investigator_affiliation>
    <investigator_full_name>Peter A Campochiaro, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>AMD</keyword>
  <keyword>Almera</keyword>
  <keyword>Steroid</keyword>
  <keyword>Macular</keyword>
  <keyword>ARMD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluocinolone Acetonide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Fluocinolone Acetonide: 0.2 ug/Day Implant</title>
          <description>Dose 0.2 ug/day Medidur implant</description>
        </group>
        <group group_id="P2">
          <title>Fluocinolone Acetonide: 0.5 ug/Day Implant</title>
          <description>Dose 0.5 ug/day Medidur implant</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Fluocinolone Acetonide: 0.2 ug/Day Implant</title>
          <description>Dose 0.2 ug/day Medidur implant
Fluocinolone Acetonide/Medidur : 0.2 ug/day implant</description>
        </group>
        <group group_id="B2">
          <title>Fluocinolone Acetonide: 0.5 ug/Day Implant</title>
          <description>Dose 0.5 ug/day Medidur implant
Fluocinolone Acetonide/Medidur : 0.5 ug/day implant</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
            <count group_id="B2" value="2"/>
            <count group_id="B3" value="6"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75.4" spread="5.3"/>
                    <measurement group_id="B2" value="75.9" spread="3.9"/>
                    <measurement group_id="B3" value="75.5" spread="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Change From Baseline in Visual Acuity</title>
        <description>Visual acuity is measured using ETDRS charts at 4 meters.</description>
        <time_frame>6 mos</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fluocinolone Acetonide: 0.2 ug/Day Implant</title>
            <description>Dose 0.2 ug/day Medidur implant
Fluocinolone Acetonide/Medidur : 0.2 ug/day implant</description>
          </group>
          <group group_id="O2">
            <title>Fluocinolone Acetonide: 0.5 ug/Day Implant</title>
            <description>Dose 0.5 ug/day Medidur implant
Fluocinolone Acetonide/Medidur : 0.5 ug/day implant</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Visual Acuity</title>
          <description>Visual acuity is measured using ETDRS charts at 4 meters.</description>
          <units>ETDRS letters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="5.19"/>
                    <measurement group_id="O2" value="1.0" spread="8.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Developing Cataracts</title>
        <time_frame>6 mos</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fluocinolone Acetonide: 0.2 ug/Day Implant</title>
            <description>Dose 0.2 ug/day Medidur implant
Fluocinolone Acetonide/Medidur : 0.2 ug/day implant</description>
          </group>
          <group group_id="O2">
            <title>Fluocinolone Acetonide: 0.5 ug/Day Implant</title>
            <description>Dose 0.5 ug/day Medidur implant
Fluocinolone Acetonide/Medidur : 0.5 ug/day implant</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Developing Cataracts</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in IOP From Baseline</title>
        <description>IOP stands for intra ocular pressure</description>
        <time_frame>6 mos</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fluocinolone Acetonide: 0.2 ug/Day Implant</title>
            <description>Dose 0.2 ug/day Medidur implant
Fluocinolone Acetonide/Medidur : 0.2 ug/day implant</description>
          </group>
          <group group_id="O2">
            <title>Fluocinolone Acetonide: 0.5 ug/Day Implant</title>
            <description>Dose 0.5 ug/day Medidur implant
Fluocinolone Acetonide/Medidur : 0.5 ug/day implant</description>
          </group>
        </group_list>
        <measure>
          <title>Change in IOP From Baseline</title>
          <description>IOP stands for intra ocular pressure</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.30" spread="5.81"/>
                    <measurement group_id="O2" value="2.65" spread="1.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Fluocinolone Acetonide: 0.2 ug/Day Implant</title>
          <description>Dose 0.2 ug/day Medidur implant
Fluocinolone Acetonide/Medidur : 0.2 ug/day implant</description>
        </group>
        <group group_id="E2">
          <title>Fluocinolone Acetonide: 0.5 ug/Day Implant</title>
          <description>Dose 0.5 ug/day Medidur implant
Fluocinolone Acetonide/Medidur : 0.5 ug/day implant</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Cataract Operation</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Cataract Operation Complication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <description>Study Eye</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Cataract Subcapsular</sub_title>
                <description>Study Eye</description>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contrast Media Reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Intraocular Pressure Increased</sub_title>
                <description>Study Eye</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Cataract Operation Complication</sub_title>
                <description>Study Eye</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Peter Campochiaro, M.D.</name_or_title>
      <organization>Johns Hopkins University</organization>
      <email>pcampo@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

